Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 3/20 | 0.76 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
| ▸ | AKR1C4 | P17516 | 4/20 | 0.65 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.65 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.65 |
| ▸ | AKR1C1 | Q04828 | 4/20 | 0.65 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.64 |
| ▸ | MEN1 | O00255 | 5/20 | 0.64 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | AR | P10275 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2338616 | 0.86 | HCAR3 (1.00) | HCAR3MAPTHPGDAKR1C4AKR1C3 | |
| SCHEMBL20897509 | 0.85 | HCAR3 (0.77) | HCAR3MAPTHPGDAKR1C4AKR1C3 | |
| SCHEMBL23675146 | 0.85 | HCAR3 (0.76) | HCAR3MAPTHPGDAKR1C4AKR1C3 | |
| SCHEMBL11528981 | 0.85 | HCAR3 (0.76) | HCAR3MAPTHPGDAKR1C4AKR1C3 | |
| SCHEMBL2338144 | 0.85 | HCAR3 (0.76) | HCAR3MAPTHPGDAKR1C4AKR1C3 | |
| SCHEMBL2648562 | 0.85 | HCAR3 (0.76) | HCAR3MAPTHPGDAKR1C4AKR1C3 | |
| SCHEMBL4491879 | 0.82 | HCAR3 (0.72) | HCAR3MAPTHPGDAKR1C4AKR1C3 | |
| SCHEMBL16577821 | 0.81 | HCAR3 (0.70) | HCAR3MAPTHPGDAKR1C4AKR1C3 | |
| SCHEMBL7439285 | 0.80 | AKR1C4 (0.72) | HCAR3MAPTHPGDAKR1C4AKR1C3 | |
| SCHEMBL4942171 | 0.79 | ALDH1A1 (0.68) | HCAR3MAPTAKR1C4AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485658-B2 | N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-7485658-B2 | N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-7485658-B2 | N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| EP-1664032-B1 | N-SUBSTITUTED PYRAZOLYL-AMIDYL-BENZIMIDAZOLYL C-KIT INHIBITORS | OSI PHARM INC (US) | 2008-11-05 | — | — | EP | disclosed |
| EP-1664032-B1 | N-SUBSTITUTED PYRAZOLYL-AMIDYL-BENZIMIDAZOLYL C-KIT INHIBITORS | OSI PHARM INC (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20080221187-A9 | N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors | OSI PHARMACEUTICALS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221187-A9 | N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors | OSI PHARMACEUTICALS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221187-A9 | N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors | OSI PHARMACEUTICALS, INC. | 2008-09-11 | — | — | US | disclosed |
| CN-1839130-A | N-substituted pyrazolyl-amidyl-benzimidazolyl C-KIT inhibitors | OSI PHARM INC (US) | 2006-09-27 | — | — | CN | disclosed |
| EP-1664032-A1 | N-SUBSTITUTED PYRAZOLYL-AMIDYL-BENZIMIDAZOLYL C-KIT INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20060035951-A1 | N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors | BOLGER JOSHUA | 2006-02-16 | — | — | US | disclosed |
| WO-2005021537-A1 | N-SUBSTITUTED PYRAZOLYL-AMIDYL-BENZIMIDAZOLYL C-KIT INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221187-A9 | N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors | KIT, TNNI3K, CHUK | HCAR3 3693/4885MAPT 4501/4885HPGD 756/4885 |
| US-20060035951-A1 | N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors | KIT, TNNI3K, CHUK | HCAR3 3693/4885MAPT 4501/4885HPGD 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.